乳腺癌、结肠癌和直肠癌患者的尿表皮生长因子（hEGF）水平。
Urinary epidermal growth factor (hEGF) levels in patients with carcinomas of the breast, colon and rectum.
作者信息
Sweetenham J W, Davies D E, Warnes S, Alexander P
机构信息
C.R.C. Wessex Medical Oncology Unit, Southampton General Hospital, UK.
出版信息
Br J Cancer. 1990 Sep;62(3):459-61. doi: 10.1038/bjc.1990.318.
A specific two-site ELISA for human epidermal growth factor (hEGF) has been used to measure urinary hEGF/creatinine ratios in 30 normal subjects, 30 hospital in-patients with breast cancer and 30 hospital in-patients with colonic or rectal cancer. There was no significant difference between patients with breast cancer and controls. Although a statistically significant difference between patients with colorectal cancer and controls was observed, the biological significance of this observation is doubtful. No clear effect of the presence of breast or colorectal carcinoma on the urinary excretion of hEGF has been observed.
一种用于检测人表皮生长因子（hEGF）的特异性双位点酶联免疫吸附测定法（ELISA），被用于测量30名正常受试者、30名乳腺癌住院患者以及30名结肠或直肠癌住院患者的尿hEGF/肌酐比值。乳腺癌患者与对照组之间无显著差异。虽然观察到结肠直肠癌患者与对照组之间存在统计学上的显著差异，但这一观察结果的生物学意义值得怀疑。未观察到乳腺癌或结肠直肠癌的存在对hEGF尿排泄有明显影响。
Zotero 插件